ES2584858T3 - Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol - Google Patents

Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol Download PDF

Info

Publication number
ES2584858T3
ES2584858T3 ES14150805.1T ES14150805T ES2584858T3 ES 2584858 T3 ES2584858 T3 ES 2584858T3 ES 14150805 T ES14150805 T ES 14150805T ES 2584858 T3 ES2584858 T3 ES 2584858T3
Authority
ES
Spain
Prior art keywords
days
hours
polyol
composition
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14150805.1T
Other languages
English (en)
Inventor
Bhagwati P. Kabra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42364357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2584858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2584858T3 publication Critical patent/ES2584858T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición oftálmica de múltiples dosis que comprende: brinzolamida, brimonidina o una combinación de las mismas como agente terapéutico; un primer poliol, seleccionándose el primer poliol de manitol, sorbitol o una combinación de los mismos, siendo la concentración del primer poliol de al menos el 0,01% en p/v pero no mayor del 0,5% en p/v; un segundo poliol, seleccionándose el segundo poliol de propilenglicol, glicerina o una combinación de los mismos, siendo la concentración del segundo poliol de al menos el 0,1% en p/v pero menor del 5% en p/v de la composición; una cantidad eficaz de borato, siendo la cantidad eficaz de al menos el 0,05% en p/v y menor del 0,5% en p/v de la composición global; BAC como conservante antimicrobiano, siendo la concentración de BAC en la composición mayor del 0,00001% en p/v pero menor del 0,0035% en p/v; y agua.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
pueden usarse para suspensiones oftálmicas de fármacos tales como brinzolamida, roscovitina, amfenac amida, dexametasona, inhibidor de bradicinina, acetato de anecortavo, tandospirona, combinaciones de los mismos y sus combinaciones con otros fármacos.

Tabla C: ejemplos A a C con el 0,002% de BAC
Composición
A COMPARATIVO B COMPARATIVO C
Carbómero 974 P
0,45 0,45 0,45
Tiloxapol
0,025 0,025 0,025
Ácido bórico
0,3 0,6 0,3
Manitol
0,3 2,0 2
Propilenglicol
0,75 1 0,75
Cloruro de sodio
0,3 Ninguno Ninguno
Cloruro de benzalconio
0,002 0,002 0,002
Edetato de disodio
Ninguno Ninguno Ninguno
Hidróxido de sodio/HCl
pH 7,0 pH 7,0 pH 7,0
Agua purificada
CS CS CS
Osmolalidad
279 324 259
Viscosidad (cps) a 120 s-1
49,6 68,2 127,9
Viscosidad (cps) a 12 s-1
144,4 210,4 480,7
Microorganismos, tiempo
Criterios de la Ph. Eur. A Criterios de la Ph. Eur. B Reducciones log
S. aureus 6 horas 24 horas 7 días 14 días 28 días
2,0 3,0 NRa -1,0 3,0 NIb 4,6 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 2,5 4,9 4,9 4,9 4,9
P. aeruginosa 6 horas 24 horas 7 días 14 días 28 días
2,0 3,0 NR -1,0 3,0 NI 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 4,8 4,8 4,8 4,8 4,8
E. colic 6 horas 24 horas 7 días 14 días 28 días
NAd NA 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 3,0 5,0 5,0 5,0 5,0
C. albicans 7 días 14 días 28 días
2,0 NI NI -1,0 NI 4,7 4,7 4,7 4,7 4,7 4,7 4,8 4,8 4,8
A. niger 7 días 14 días 28 días
2,0 NI NI -1,0 NI 3,1 3,6 5,2 3,1 4,2 5,2 3,7 4,3 5,1
aNR = Sin recuperación bNI = Sin aumento cLa Ph. Eur. No tiene requisito para E. Coli dNA = No aplicable
Ejemplo D
El ejemplo D presentado en la tabla 3 es una composición con el 0,002% de BAC, ácido bórico y dos polioles diferentes y se proyecta para cumplir con los criterios de PET de la Ph. Eur B y A.
Tabla D: Ejemplo D con el 0,002% de BAC
Composición
D
Ácido bórico
0,3
Sorbitol
0,25
Propilenglicol
1,6
10
imagen9
Cada una de las composiciones H-J, entre otros usos, puede usarse como vehículos de suspensión para suspender agentes terapéuticos.
Composición
H I J
Cloruro de sodio
0,15 0,3 Ninguno
Cloruro de benzalconio
0,001 0,001 0,001
Hidróxido de sodio/HCl
pH 7,0 pH 7,0 pH 7,0
Agua purificada
CS CS CS
Osmolalidad
278 274 278
Viscosidad (cps) a 120 s-1
63,1 53,8 59,1
Viscosidad (cps) a 12 s-1
169 149 172
S. aureus 6 horas 24 horas 7 días 14 días 28 días
0,2 2,6 5,0 5,0 5,0 0,0 1,4 5,0 5,0 5,0 0,2 3,0 5,0 5,0 5,0
P. aeruginosa 6 horas 24 horas 7 días 14 días 28 días
4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9
E. coli 6 horas 24 horas 7 días 14 días 28 días
1,4 3,1 5,0 5,0 5,0 1,4 3,4 5,0 5,0 5,0 3,1 5,0 5,0 5,0 5,0
C. albicans 7 días 14 días 28 días
3,0 4,3 4,8 3,5 4,8 4,8 4,8 4,8 4,8
A. niger 7 días 14 días 28 días
3,2 3,7 3,6 3,5 3,4 3,0 3,6 3,5 3,4

Tabla G: Formulaciones de roscovitina con baja cantidad de BAC, ácido bórico y dos polioles
Composición
K
Roscovitina (AL-39256)
1
Carbómero 974P
0,45
Tiloxapol
0,025
Ácido bórico
0,3
Manitol
0,3
Propilenglicol
0,75
Cloruro de sodio
0,28
Cloruro de benzalconio
0,003
Hidróxido de sodio/HCl
pH 7,2
Agua purificada
CS
Osmolalidad (mOsm/kg)
271
Viscosidad (cps) a 12 s-1
198,1
Viscosidad (cps) a 120 s-1
66,5
S. aureus
6 horas 24 horas 7 días 14 días 28 días 5,1 5,1 5,1 5,1 5,1
P. aeruginosa
6 horas 24 horas 7 días 14 días 28 días 4,9 4,9 4,9 4,9 4,9
E. colic
6 horas 4,9
12
Composición
K
24 horas
4,9
7 días
4,9
14 días
4,9
28 días
4,9
C. albicans
7 días 4,8
14 días
4,8
28 días
4,8
A. niger
7 días 5,1
14 días
5,1
28 días
5,1
La composición K presenta una resistencia a la normalización de lágrimas de aproximadamente 4,4.
Tabla H: Formulaciones de brinzolamida y brinzolamida/brimonidina con baja cantidad de BAC, ácido bórico y dos polioles
Composición
M N
Brinzolamida
1,0 1,0
Brimonidina
0,15 0,15
Carbopol 974P
0,4 0,4
Tiloxapol
0,025 0,025
Ácido bórico
0,3 0,3
Manitol
0,3 0,3
Propilenglicol
0,75 0,75
Cloruro de sodio
0,23 0,23
Cloruro de benzalconio
0,003 0,003
Hidróxido de sodio y/o ácido clorhídrico
CS para pH 6,5 ± 0,2 CS para pH 6,5 ± 0,2
Agua purificada
CS hasta el 100% CS hasta el 100%
S. aureus 6 horas 24 horas 7 días 14 días 28 días
5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0
P. aeruginosa 6 horas 24 horas 7 días 14 días 28 días
5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0
E. colic 6 horas 24 horas 7 días 14 días 28 días
5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0
C. albicans 7 días 14 días 28 días
4,8 4,8 4,8 4,8 4,8 4,8
A. niger 7 días 14 días 28 días
4,3 4,1 4,2 4,4 4,3 4,1

Tabla I: Ejemplo O a V
Las composiciones M y N presentan una resistencia a la normalización de lágrimas de aproximadamente 18.
Los ejemplos O a V muestran que tanto la osmolalidad como la viscosidad de formulaciones que contienen carbómero pueden obtenerse en el intervalo deseado usando cloruro de sodio al tiempo que se mantiene la concentración de sodio inferior al 0,4%.
13
imagen10

Claims (1)

  1. imagen1
    imagen2
ES14150805.1T 2009-06-19 2010-06-17 Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol Active ES2584858T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847209P 2009-06-19 2009-06-19
US218472P 2009-06-19

Publications (1)

Publication Number Publication Date
ES2584858T3 true ES2584858T3 (es) 2016-09-29

Family

ID=42364357

Family Applications (3)

Application Number Title Priority Date Filing Date
ES14150805.1T Active ES2584858T3 (es) 2009-06-19 2010-06-17 Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
ES10727317.9T Active ES2461617T3 (es) 2009-06-19 2010-06-17 Composiciones farmacéuticas acuosas que contienen complejos borato-polioles
ES16159225T Active ES2803648T3 (es) 2009-06-19 2010-06-17 Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10727317.9T Active ES2461617T3 (es) 2009-06-19 2010-06-17 Composiciones farmacéuticas acuosas que contienen complejos borato-polioles
ES16159225T Active ES2803648T3 (es) 2009-06-19 2010-06-17 Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol

Country Status (26)

Country Link
US (3) US9044484B2 (es)
EP (4) EP2442790B1 (es)
JP (3) JP6017956B2 (es)
KR (1) KR101738502B1 (es)
CN (2) CN104707145A (es)
AR (2) AR077126A1 (es)
AU (1) AU2010262898B2 (es)
BR (1) BRPI1015996B8 (es)
CA (1) CA2763778C (es)
CL (1) CL2010000634A1 (es)
CY (2) CY1117835T1 (es)
DK (3) DK2722035T3 (es)
ES (3) ES2584858T3 (es)
HR (2) HRP20160953T1 (es)
HU (2) HUE049477T2 (es)
LT (1) LT3045164T (es)
MX (1) MX2011013107A (es)
PL (3) PL2442790T3 (es)
PT (3) PT2442790E (es)
RU (1) RU2563125C2 (es)
SI (3) SI2442790T1 (es)
SM (1) SMT201600249B (es)
TW (1) TWI489997B (es)
UY (1) UY32709A (es)
WO (1) WO2010148190A1 (es)
ZA (1) ZA201108384B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2254549E (pt) * 2008-03-17 2014-01-30 Alcon Res Ltd Composições farmacêuticas aquosas que contêm complexos de borato-poliol
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
CA2824433C (en) 2011-01-18 2019-11-12 Senju Pharmaceutical Co., Ltd. Aqueous liquid bromfenac composition having preservative efficacy
KR20140022900A (ko) 2011-04-22 2014-02-25 알콘 리서치, 리미티드 2종의 상이한 점도 증강제를 포함하는 점도 증강 시스템을 갖는 안과 조성물
EP3045163A1 (en) 2011-04-22 2016-07-20 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
WO2014121027A1 (en) 2013-02-01 2014-08-07 Oculars Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
JP6353048B2 (ja) 2013-08-20 2018-07-04 スリーエム イノベイティブ プロパティズ カンパニー ホウ素−シランポリエーテル錯体
WO2017217450A1 (ja) * 2016-06-15 2017-12-21 千寿製薬株式会社 眼科用医薬製品
JP6247430B1 (ja) * 2016-06-15 2017-12-13 千寿製薬株式会社 眼科用医薬製品
CN106237337B (zh) * 2016-08-05 2019-11-08 河南中帅医药科技股份有限公司 一种液体药物制剂用防腐组合物
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP7413040B2 (ja) 2018-02-21 2024-01-15 三菱重工サーマルシステムズ株式会社 スクロール流体機械及びその設計方法
EP3866790A4 (en) 2018-10-15 2022-08-03 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
JP7670945B2 (ja) 2018-10-26 2025-05-01 オーパス・ジェネティクス・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
HRP20220165T1 (hr) 2019-07-23 2022-04-29 Nicox Ophthalmics, Inc. Postupak priprave sterilnih oftalmoloških vodenih suspenzija nanokristala flurikazona-propionata oblika a
US20230218611A1 (en) * 2020-04-29 2023-07-13 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
GB2084870B (en) * 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP3058656B2 (ja) 1990-06-18 2000-07-04 トーメー産業株式会社 コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法
US5422073A (en) * 1990-12-27 1995-06-06 Allergan, Inc. Method and composition for disinfecting contact lenses
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
ATE300936T1 (de) * 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) * 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
CA2088927A1 (en) 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (es) 1993-11-12 1996-04-21 Ciba Geigy Ag
WO1996003158A1 (en) * 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6024954A (en) * 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1996029049A1 (en) * 1995-03-20 1996-09-26 Unilever Plc Liquid cleansing formulations
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
AU4428397A (en) * 1996-09-20 1998-04-14 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
JPH10130156A (ja) 1996-10-30 1998-05-19 Teika Seiyaku Kk 点眼剤組成物
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
WO1998025649A1 (en) * 1996-12-13 1998-06-18 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
DE69839355T2 (de) * 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6034043A (en) * 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CN1477929A (zh) * 2000-11-29 2004-02-25 ��˹��ŵ�� 水性消毒系统
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4844706B2 (ja) * 2001-03-12 2011-12-28 ライオン株式会社 眼科用組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI322828B (en) * 2002-12-23 2010-04-01 Alcon Inc Use of multifunctional surface active agents to clean contact lenses
PT1586316E (pt) * 2003-01-21 2008-05-28 Senju Pharma Co Preparação líquida aquosa contendo ácido 2-amino-3-(4- bromobenzoil)fenilacético
US20050124702A1 (en) 2003-12-09 2005-06-09 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
ATE428684T1 (de) * 2003-12-09 2009-05-15 Alcon Inc Verwendung von bisaminen zur verstärkung der antimikrobiellen wirkung von wässrigen zusammensetzungen
EP1696878A1 (en) * 2003-12-11 2006-09-06 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
US20070293558A1 (en) * 2004-10-13 2007-12-20 Ying-Duo Gao Ophthalmic Compositions for Treating Ocular Hypertension
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
US20070297990A1 (en) * 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
CN101516332B (zh) * 2006-09-21 2012-12-19 爱尔康研究有限公司 自身防腐的水性药物组合物
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
WO2008042619A2 (en) 2006-09-28 2008-04-10 Alcon Research, Ltd. Self-preserved aqueous pharmaceutical compositions
WO2008052037A2 (en) * 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
PT2254549E (pt) 2008-03-17 2014-01-30 Alcon Res Ltd Composições farmacêuticas aquosas que contêm complexos de borato-poliol
US7999064B2 (en) 2009-04-23 2011-08-16 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods and associated formulations
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物

Also Published As

Publication number Publication date
AU2010262898A1 (en) 2011-12-15
SMT201600249B (it) 2016-08-31
US20100324031A1 (en) 2010-12-23
AR122017A2 (es) 2022-08-03
CY1123120T1 (el) 2021-10-29
CL2010000634A1 (es) 2011-03-11
HUE049477T2 (hu) 2020-09-28
DK2722035T3 (en) 2016-08-01
WO2010148190A1 (en) 2010-12-23
ES2461617T3 (es) 2014-05-20
SI2722035T1 (sl) 2016-09-30
KR20120028390A (ko) 2012-03-22
BRPI1015996A8 (pt) 2018-01-09
US9421265B2 (en) 2016-08-23
CN102802604A (zh) 2012-11-28
HRP20200979T1 (hr) 2020-10-16
EP3045164B1 (en) 2020-04-15
UY32709A (es) 2010-12-31
AU2010262898B2 (en) 2015-02-12
LT3045164T (lt) 2020-07-27
RU2012101782A (ru) 2013-07-27
BRPI1015996B8 (pt) 2021-05-25
BRPI1015996B1 (pt) 2020-08-11
SI3045164T1 (sl) 2020-08-31
HK1194007A1 (en) 2014-10-10
ES2803648T3 (es) 2021-01-28
DK3045164T3 (da) 2020-07-13
CA2763778C (en) 2016-02-02
HUE030435T2 (en) 2017-05-29
HRP20160953T1 (hr) 2016-10-07
EP2722035A1 (en) 2014-04-23
CA2763778A1 (en) 2010-12-23
US9044484B2 (en) 2015-06-02
PT2722035T (pt) 2016-08-02
US20160324967A1 (en) 2016-11-10
TW201100103A (en) 2011-01-01
EP2722035B1 (en) 2016-04-27
AR077126A1 (es) 2011-08-03
PT2442790E (pt) 2014-05-12
JP2016183198A (ja) 2016-10-20
EP2442790B1 (en) 2014-03-26
CY1117835T1 (el) 2017-05-17
CN104707145A (zh) 2015-06-17
JP2012530712A (ja) 2012-12-06
JP6017956B2 (ja) 2016-11-02
HK1163521A1 (en) 2012-09-14
EP2442790A1 (en) 2012-04-25
EP3437634A1 (en) 2019-02-06
CN102802604B (zh) 2016-02-10
JP2014198729A (ja) 2014-10-23
BRPI1015996A2 (pt) 2016-04-26
MX2011013107A (es) 2012-01-20
PL2442790T3 (pl) 2014-08-29
US20150224196A1 (en) 2015-08-13
KR101738502B1 (ko) 2017-05-22
RU2563125C2 (ru) 2015-09-20
PL2722035T3 (pl) 2016-11-30
PL3045164T3 (pl) 2020-10-19
TWI489997B (zh) 2015-07-01
EP3045164A1 (en) 2016-07-20
ZA201108384B (en) 2013-01-30
DK2442790T3 (da) 2014-04-14
PT3045164T (pt) 2020-07-14
SI2442790T1 (sl) 2014-05-30

Similar Documents

Publication Publication Date Title
ES2584858T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
ES2627437T3 (es) Composiciones de fosfolípido para cuidado de lentes de contacto y preservación de composiciones farmacéuticas
ES2301964T3 (es) Preparado liquido acuoso que contiene acido 2-amino-3-(4-bromobenzoil)fenilacetico.
ES2198127T3 (es) Composiciones farmaceuticas autoclaveables que contienen un agente quelante.
ES2324058T3 (es) Solucion oftalmica de bimatoprost mejorada.
ES2638771T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
PT739197E (pt) Composicoes de farmacos oftalmicos conservados contendo compostos de amonio quaternario polimericos
PT1819362E (pt) Formulações tópicas de nepafenac
JP2013525493A5 (es)
AR069438A1 (es) Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
JPWO2018066651A1 (ja) 眼科用製品及び粘度低下抑制方法
JP2014214085A (ja) オロパタジン含有水性組成物
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
JP5246182B2 (ja) 点眼剤、防腐剤及び防腐力向上剤
JP2013144671A (ja) 眼科用水性組成物
ES2294361T3 (es) Colirios estables que contienen latanoprost como principio activo.
AR106691A1 (es) Formulaciones oftálmicas de escualamina
JP5149308B2 (ja) 局所的鼻腔投与のためのオロパタジンの製剤
JP2013181020A (ja) 眼科用組成物
JP6161500B2 (ja) ブロムフェナク含有組成物
ES2337501T3 (es) Preparacion oftalmica que comprende goma de xantano y terpenoide.
JP6345492B2 (ja) 点眼剤
ES2664053T3 (es) Composición líquida acuosa que contiene ácido 2-amino-3-(4-bromobenzoil)fenil-láctico
PE20211218A1 (es) Suspensiones liquidas de paracetamol